Market Overview:

According to our new research study on “Gastroparesis Market Forecast to 2027 – COVID-19 Impact and Analysis – by Type, Drug Class Type, and Distribution Channel,” the market is expected to reach US$ 6,025.11 million by 2027 from US$ 4,338.61 million in 2019; it is estimated to grow at a CAGR of 4.3% from 2020 to 2027. The report highlights trends prevailing in the market, and the factors driving and hindering the market growth.Gastroparesis is a medical condition characterized by the disability of stomach to empty itself of food in the usual way. Damaged nerves such as vagus nerves and muscles associated with gastric motility may also lead to gastroparesis. The condition is commonly observed in diabetic people. Gastroparesis can be classified as diabetic, idiopathic, and post-surgical on the basis of the cause. Apart from these, viral infections, nerve-related diseases, excessive narcotics and several antidepressant consumptions, and amyloidosis may also lead to the onset of gastroparesis.

Get Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00008992/

On the basis of drug class type, the gastroparesis market is segmented into prokinetic agents, botulinum toxin injection, and antiemetic agents. In 2019, the prokinetic agents segment held the largest share of the market, and it is further estimated to register the highest CAGR of 4.7% during the forecast period. The growth of the market for this segment is attributed to the increasing preference for prokinetic agents for the treatment of gastroparesis.

The COVID-19 pandemic has disrupted supply chain of over-the-counter (OTC) and prescription drugs, and this is likely to limit the market growth in the next few quarters. Moreover, prime focus of health care providers and medical industries on COVID-19 has led to the lowered focus on the diagnosis and treatment for gastroparesis, which is limiting the market growth to a certain extent.

EVOKE PHARMA, Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.), Johnson And Johnson Services, Inc., Allergan Plc, NEUROGASTRX, INC., TEVA PHARMACEUTICAL INDUSTRIES LTD, Pfizer Inc., ANI Pharmaceuticals, Inc., Ipca Laboratories Ltd., and Cinrx Pharma, LLC (Cindome Pharma) are among the leading companies operating in the gastroparesis market.

Buy Now :  https://www.theinsightpartners.com/buy/TIPRE00008992/

The report segments global Gastroparesis market as follows:

By Type

• Idiopathic
• Diabetic
• Post-surgical
• Others

By Drug Class Type

• Prokinetic Agents
• Botulinum Toxin Injections
• Antiemetic Agents

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific (APAC)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of APAC
• Middle East and Africa (MEA)
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of MEA
• South and Central America (SCAM)
  • Brazil
  • Argentina
  • Rest of SCAM

Our Most Selling Reports

Healthcare Actuator Market Growth 2022-2028

Home Healthcare Market Growth 2022-2028

Human Microbiome Market Growth 2022-2028

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876